Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...
EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ -- Novartis is inviting patient advocacy organizations to submit proposals for programs that offer to expand and improve understanding of biomarker ...
Jay Bradner, M.D., has revealed that Novartis has scrapped one-fifth of its drug programs. The cull is designed to limit Novartis’ pipeline to potentially transformative therapies that fit with the ...
Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare inequities at Historically Black Medical School ...
Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development of the DP2 antagonist in asthma. The setback means Amgen, AstraZeneca ...
Novartis Pharmaceuticals Corporation 1 (Novartis) recently entered into a civil settlement agreement with the Department of Justice (DOJ) to resolve allegations that the company paid health care ...
EAST HANOVER, N.J., July 12, 2023 /PRNewswire/ -- Novartis and the Novartis US Foundation proudly announce the significant expansion of Beacon of Hope, our 10-year commitment to co-create programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results